SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-082585
Filing Date
2021-06-17
Accepted
2021-06-17 16:02:17
Documents
6
Period of Report
2021-06-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2119126d1_8k.htm 8-K 38647
2 EXHIBIT 10.1 tm2119126d1_ex10-1.htm EX-10.1 154885
3 EXHIBIT 10.2 tm2119126d1_ex10-2.htm EX-10.2 41250
4 EXHIBIT 10.3 tm2119126d1_ex10-3.htm EX-10.3 30885
5 EXHIBIT 10.4 tm2119126d1_ex10-4.htm EX-10.4 31795
6 EXHIBIT 10.5 tm2119126d1_ex10-5.htm EX-10.5 28936
  Complete submission text file 0001104659-21-082585.txt   327913
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 211024664
SIC: 2835 In Vitro & In Vivo Diagnostic Substances